Alvotech Faces Securities Claims After 34% Stock Drop Following FDA Response
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Significant Stock Drop: Alvotech's stock plummeted 34% on November 3, 2025, following the FDA's complete response letter regarding its Biologics License Application, indicating serious market concerns about the company's compliance and future prospects.
- Legal Investigation Launched: The Rosen Law Firm is investigating potential securities fraud claims against Alvotech, suggesting that investors who purchased its securities may be entitled to compensation without any out-of-pocket costs, reflecting diminished investor confidence in the company's transparency.
- Class Action Preparation: The firm is preparing a class action lawsuit against Alvotech to recover investor losses, highlighting heightened scrutiny on corporate governance and compliance issues within the company.
- FDA Review Findings: The FDA's statement on November 2, 2025, noted deficiencies found during the July 2025 inspection of Alvotech's Reykjavik facility that must be resolved before approval can be granted, further exacerbating investor anxiety regarding the company's operational integrity.
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALVO is 10.67 USD with a low forecast of 8.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.640
Low
8.00
Averages
10.67
High
14.00
Current: 4.640
Low
8.00
Averages
10.67
High
14.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
